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Tobacco use is the leading preventable cause of death in 
the United States. Visual impairment, a common cause of 
disability in the United States, is associated with shorter 
life expectancy and lower quality of life. The relationship 
between smoking and visual impairment is not clearly 
understood. We assessed the association between smok-
ing and visual impairment among older adults with age-
related eye diseases.
Methods
We analyzed Behavioral Risk Factor Surveillance System 
data from 2005 through 2008 on older adults with age-
related eye diseases (cataract, glaucoma, age-related macu-
lar degeneration, and diabetic retinopathy; age ≥50 y, N = 
36,522). Visual impairment was defined by self-reported 
difficulty in recognizing a friend across the street or dif-
ficulty in reading print or numbers. Current smokers were 
respondents who reported having smoked at least 100 
cigarettes ever and still smoked at the time of interview. 
Former smokers were respondents who reported having 
ever smoked at least 100 cigarettes but currently did not 
smoke. We used multivariate logistic regressions to exam-
ine the association and to adjust for potential confounders.
Results
Among respondents with age-related eye diseases, the 
estimated prevalence of visual impairment was higher 
among current smokers (48%) than among former smok-
ers (41%, P < .05) and respondents who had never smoked 
(42%, P < .05). After adjustment for age, sex, race/ethnic-
ity, education, and general health status, current smokers 
with age-related eye diseases were more likely to have 
visual impairment than respondents with age-related eye 
diseases who had never smoked (odds ratio, 1.16, P < .05). 
Furthermore, respondents with cataract who were current 
smokers were more likely to have visual impairment than 
respondents with cataract who had never smoked (predic-
tive margin, 44% vs 40%, P = .03), and the same was true 
for respondents with age-related macular degeneration 
(65% of current smokers vs 57% of never smokers, P = .02). 
This association did not hold true among respondents with 
glaucoma or diabetic retinopathy.
Conclusion
Smoking is linked to self-reported visual impairment 
among older adults with age-related eye diseases, par-
ticularly cataract and age-related macular degeneration. 
Longitudinal evaluation is needed to assess smoking 
cessation’s effect on vision preservation.
Introduction
Tobacco use causes approximately 443,000 deaths annu-
ally and is the leading preventable cause of death in the 
United States (1). Smoking harms nearly every organ of 
the body, causes many diseases, and worsens the general 
health of smokers. Moreover, secondhand smoke causes 
diseases and premature death in nonsmoking children and 
Xinzhi Zhang, MD, PhD; Jennifer Kahende, PhD; Amy Z. Fan, MD, PhD; Lawrence Barker, PhD; 
Theodore J. Thompson, MS; Ali H. Mokdad, PhD; Yan Li, MD, MPH; Jinan B. Saaddine, MD, MPH
 www.cdc.gov/pcd/issues/2011/jul/10_0156.htm • Centers for Disease Control and Prevention 1
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the 
Centers for Disease Control and Prevention.
VOLUME 8: NO. 4
JULY 2011
2 Centers for Disease Control and Prevention • www.cdc.gov/pcd/issues/2011/jul/10_0156.htm
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position  
of the Centers for Disease Control and Prevention.
adults (2). Smoking annually results in an estimated $96 
billion in direct costs and $97 billion in productivity losses 
(1). Lifetime additional direct medical expenditures among 
smokers were $16,454 for men and $19,275 for women in 
2004 (3).
Blindness and visual impairment are among the 10 most 
common causes of disability in the United States (4) and 
are associated with shorter life expectancy and lower qual-
ity of life (5,6). In 2000, blindness or low vision, mainly 
caused by age-related eye diseases (ARED, including cata-
ract, glaucoma, age-related macular degeneration [AMD], 
and diabetic retinopathy [DR]), affected more than 3.3 
million Americans aged 40 years or older; this number 
is predicted to increase more than 50% by 2020 (7). The 
annual economic effect of major vision problems among 
the adult population aged 40 years or older was more than 
$51 billion in 2004 (8,9).
Many studies have explored the associations between 
smoking and ARED. The 2004 Surgeon General’s report 
on smoking concluded that a causal relationship between 
smoking and nuclear cataract exists and found evidence 
that was suggestive of a relationship between smoking 
and AMD (10). The report suggested an absence of a caus-
al relationship between smoking and DR and found that 
evidence of a relationship between smoking and glaucoma 
was not conclusive (10). ARED is strongly associated with 
visual impairment (7). However, the relationship between 
smoking and visual impairment has not been extensively 
assessed and is not clearly understood. We assessed the 
cross-sectional association between smoking and visual 
impairment among older adults (age ≥50 y) with ARED by 




BRFSS is a state-based, random-digit–dialed telephone 
survey of the noninstitutionalized, US civilian population 
aged 18 years or older. With approximately 350,000 adults 
participating each year, BRFSS can produce local, state, 
and national estimates on health-related information, 
including chronic illness, health behaviors, and access to 
health care. Survey methods, questionnaires, data, and 
relevant reports can be found at www.cdc.gov/brfss.
Box. States That Included the Visual Impairment and Access to Eye 
Care Module, Behavioral Risk Factor Surveillance System, 2005-2008
2005 Iowa, Louisiana, Ohio, Tennessee, and Texas
2006 Arizona, Florida, Georgia, New York, Ohio, Tennessee, and Texas
2007 Alabama, Georgia, Iowa, New York, and West Virginia
2008 Alabama, Connecticut, Indiana, Missouri, New Mexico, North 
Carolina, Tennessee, and Wyoming
The BRFSS questionnaire consists of 3 sections each year: 
core sections, optional modules, and state-added ques-
tions. The BRFSS vision module (Visual Impairment and 
Access to Eye Care) was first administered in 2005 among 
participants aged 50 years or older. We analyzed available 
data from the pooled sample of 36,522 participants aged 
50 years or older with ARED by using the vision module 
from 2005 through 2008 (n = 5,108 in 2005; n = 10,061 in 
2006; n = 7,186 in 2007; and n = 14,167 in 2008). During 
2005 through 2008, the median BRFSS response rate for 
states that included the vision module (Box) was 52.7%, 
and ranged from 34.0% to 61.5%.
Assessment of vision impairment and smoking status
Visual impairment was assessed in the vision module with 
the questions, “How much difficulty, if any, do you have 
in recognizing a friend across the street,” and “How much 
difficulty, if any, do you have reading print in newspaper, 
magazine, recipe, menu, or numbers on the telephone?” 
We classified respondents as having visual impairment 
if they answered “a little difficulty,” “moderate difficulty,” 
“extreme difficulty,” or “unable to do because of eyesight” 
to either question. If respondents usually wear glasses or 
contact lenses, they were asked to rate their ability to do 
these activities while wearing glasses or contact lenses.
Current smokers were respondents who reported smok-
ing at least 100 cigarettes during their lifetimes and 
reported continuing to smoke at the time of the interview. 
Former smokers were those who reported ever smoking 
at least 100 cigarettes but not smoking at the time of the 
interview. Never smokers were respondents who reported 
smoking fewer than 100 cigarettes in their lifetimes and 
did not smoke at the time of the interview.
Other variables
We identified 3 eye diseases (cataract, glaucoma, and 
AMD) among respondents who answered yes to the ques-
tions in the vision module, “Have you ever been told by an 
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eye doctor or other health care professional that you had 
(cataract, glaucoma, or AMD)?” We identified DR (from 
the BRFSS diabetes module) if respondents with diabe-
tes answered yes to the question, “Has a doctor ever told 
you that diabetes has affected your eyes or that you had 
retinopathy?”
We also included age (50-64 y, ≥65 y), sex (male, female), 
race/ethnicity (non-Hispanic white, non-Hispanic black, 
Hispanic, other), educational attainment (<high school 
graduate, high school graduate, some post–high school 
education), and self-assessed general health status (poor 
or fair, good, very good or excellent).
Statistical analysis
We used SAS-callable SUDAAN version 10.0 (Research 
Triangle Institute, Research Triangle Park, North 
Carolina) to account for the complex sampling design of 
BRFSS. Respondents from the states that implemented 
2 years of the vision module were given half the weight 
each year. All estimates were weighted to represent the 
sampled population. We assessed the association between 
smoking and visual impairment after adjusting for age, 
sex, race/ethnicity, educational attainment, and general 
health status. We performed logistic regression to exam-
ine the associations between smoking status and visual 
impairment to calculate odds ratios (ORs) and correspond-
ing 95% confidence intervals (CIs). Results were consid-
ered significant at P < .05.
We further examined independent associations between 
smoking and visual impairment among people with each 
ARED (cataract, glaucoma, AMD, DR). After controlling 
for other independent variables, we used multivariate 
logistic regressions to estimate the probability of having 
visual impairment among people with each ARED. We 
used Taylor linearization to estimate predictive margins 
(PMs) and their 95% CIs. Missing values were not includ-
ed in the models but were accounted for in our variance 
estimation.
Results
Demographic and health status characteristics of cur-
rent smokers, former smokers, and never smokers with 
ARED varied significantly (Table 1). Current smokers 
were younger than former and never smokers, and the 
proportion of non-Hispanic whites was higher among for-
mer smokers than current smokers and never smokers. 
We found no significant difference in the sex composition 
of former smokers, although more current smokers and 
never smokers were female than male. Education level 
was higher among former smokers and respondents who 
had never smoked than among current smokers. More for-
mer smokers and never smokers considered their health 
status as “excellent or very good” compared with current 
smokers.
Prevalence of visual impairment among respondents with 
ARED was significantly higher among current smokers 
(48%) than among former smokers (41%, P < .05) and 
never smokers (42%, P < .05) (Table 2). Compared with 
never smokers with ARED, current smokers with ARED 
had higher unadjusted odds of visual impairment (OR, 
1.31). After adjustment for age, sex, race/ethnicity, educa-
tion levels, and general health status, current smokers 
with ARED were more likely than never smokers with 
ARED to have visual impairment (OR, 1.16, P < .05), and 
odds of being visually impaired were similar between for-
mer smokers and never smokers (OR, 1.04).
Among respondents with cataract, the predictive margin 
(PM) of having visual impairment was higher among cur-
rent smokers than never smokers (44% vs 40%, P = .03) 
(Table 3). Among respondents with AMD, current smokers 
were also more likely to be visually impaired compared 
with never smokers (65% vs 57%, P = .02). The association 
was not significant among respondents with glaucoma and 
DR.
Discussion
We found that smoking is associated with self-reported 
visual impairment among older adults with ARED, espe-
cially those with cataract and AMD. Smoking may be 
linked to ocular diseases and conditions including cata-
ract, AMD, Graves’ ophthalmopathy, ocular irritation, and 
ocular ischemia (11). However, few studies have addressed 
the association between smoking and visual impairment. 
A New Zealand study suggested that the blindness of 
26.8% of registered blind people aged 55 years or older 
with AMD and 9.5% of those with cataract was attribut-
able to smoking (12). Results from the Canadian Study of 
Health and Aging suggested that the odds of self-reported 
visual impairment were 2.8 times as high among smokers 
than nonsmokers (13). Although we did not find odds this 
large, our findings suggested that smoking was indepen-
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dently associated with visual impairment among older 
adults with ARED (current smokers vs never smokers).
Smoking is strongly associated with the development of 
cataract, particularly nuclear cataract. Weintraub et al 
found that, compared with current smokers, former and 
nonsmokers were less likely to have cataract extraction 
(14). Recent findings from the Visual Impairment Project 
and the Blue Mountains Eye Study confirmed a higher 
risk and dose response of smoking and having nuclear 
cataract (15,16). We also found an independent signifi-
cant association between smoking (current smokers vs 
never smokers) and visual impairment among those with 
cataract. However, we did not find a significant difference 
between former smokers and never smokers.
Our findings suggested a strong association between 
smoking and visual impairment among people with AMD 
that is consistent with findings in the British popula-
tion. After controlling for potentially confounding factors, 
current smokers were twice as likely to have AMD that 
caused visual impairment compared with nonsmokers in a 
British study; for former smokers, the association was not 
significant (17). We found that visual impairment among 
BRFSS respondents with AMD was higher among current 
smokers than never smokers. Smoking seemed to be asso-
ciated with more severe AMD cases. Similarly, the Beaver 
Dam Eye study suggested that, after controlling for age, 
sex, and baseline AMD severity, current smokers were at 
higher risk of progression of AMD than nonsmokers (18). 
The Blue Mountains Eye Study found that current smok-
ers had an increased risk of 5-year incidence of late age-
related maculopathy lesions and developed maculopathy 
at a significantly earlier age (19). These findings suggest a 
possible effect of smoking on progression of AMD.
Although the 2004 Surgeon General’s report found insuf-
ficient evidence to infer a causal relationship between 
smoking and AMD, more recent studies indicate a strong 
association between current smoking and AMD. Smoking 
was associated with an increased frequency of recurrence 
of exudative AMD after laser photocoagulation, the only 
proven treatment for AMD (20). According to a recent 
systematic review, the evidence meets the criteria for 
causality (21). Recent findings from large population-
based studies such as the Beaver Dam Eye Study also 
indicated an increased risk of incident early AMD during 
a 15-year follow-up (18). Furthermore, the number of 
pack years of smoking was found to be strongly associ-
ated with AMD (22).
Our findings differ from those of the Beaver Dam Eye 
Study, which suggested that smoking plays a minor role in 
primary open-angle glaucoma (POAG) (23). A meta-analy-
sis of 7 reports (4 cross-sectional studies and 3 case-control 
studies) before 2003 suggested a pooled odds of POAG of 
1.37 for current smokers and 1.03 for former smokers (24). 
However, a recent systematic review of case-control and 
cohort studies by Edwards et al concluded that little evi-
dence exists for a causal association between smoking and 
development of POAG (25).
Some findings suggest a role of smoking in poorer glycemic 
control (elevated hemoglobin A1c levels), escalating insu-
lin resistance, and an increase in microvascular complica-
tions (eg, microalbuminuria) (26-28). Furthermore, current 
smokers with type 1 diabetes have higher odds of severe 
hypoglycemia than patients with type 1 diabetes who do 
not smoke (29). A prospective cohort study of CARDIA 
(coronary artery risk development in young adults) indi-
cated that both active and passive smoke exposure play a 
role in developing glucose intolerance (including impaired 
fasting glucose and diabetes) (30). Although the literature 
in general suggested little or no association between ciga-
rette smoking and the incidence or progression of DR (10), 
Mouton and Gill found that smoking influences the sever-
ity of DR (31). In this study, we found no significant rela-
tionship between smoking and visual impairment among 
BRFSS respondents with DR.
In summary, smoking is a major modifiable risk factor for 
AMD (11), and smoking is the most important modifiable 
risk factor for primary and secondary prevention of cata-
ract (10,11). A lack of awareness may exist among health 
care providers and patients about the risks of developing 
eye diseases and vision loss from smoking. Of an estimated 
61 million adults in the United States who are at high risk 
for serious vision loss due to aging, diabetes, or vision or 
eye problems, only half visit an eye care provider annually, 
making the situation even worse (32). Given the effect of 
smoking on a person’s overall health, and especially on 
sight, comprehensive tobacco control interventions, as 
recommended by the Centers for Disease Control and 
Prevention (CDC), are needed (10,33). These interventions 
include health care provider counseling, telephone quit 
lines, insurance coverage for cessation therapies, legisla-
tion of clean indoor air, and increased tobacco taxes (33).
This research is subject to several limitations. First, the 
prevalences of visual impairment and eye diseases are 
self-reported and may differ from objective clinical mea-
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surements. Data on family history of eye diseases were 
unavailable. Social desirability bias may have caused some 
current or former smokers to identify themselves as former 
or never smokers. Accordingly, the actual effect of smok-
ing may be larger than what we found. Second, the data 
were collected by telephone survey and may not be repre-
sentative of people without landline telephones. Although 
low, the BRFSS response rate is in the normal range for 
telephone surveys. BRFSS data are valid and reliable 
when compared with other household surveys (34). Third, 
institutionalized populations (eg, nursing home residents) 
are not included in the BRFSS. Fourth, only a few states 
used the BRFSS vision module, so our findings may not 
be nationally representative. Fifth, data on frequency and 
quantity of tobacco use were not obtained and could not be 
analyzed. Finally, data were cross-sectional; therefore, we 
were unable to identify causal relationships.
In conclusion, self-reported smoking is linked to self-
reported visual impairment among older adults with 
ARED. The associations between smoking and visual 
impairment were mostly observed among BRFSS respon-
dents with cataract and AMD but not among those with 
glaucoma and DR. Further longitudinal evaluation is war-
ranted to explore how smoking cessation or prevention 
might benefit vision preservation.
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Tables
Table 1. Characteristics of Study Population With Age-Related Eye Diseases, by Smoking Status, Behavioral Risk Factor Surveillance 
System, 2005-2008a
Characteristic
Current Smokers (n = 4,517), %b 
(95% CI)
Former Smokers (n = 14,165), % 
(95% CI)
Never Smokers (n = 17,651), % 
(95% CI)
Age, y
50-64 52.9 (50.-55.6) 25.9 (24.5-2.4) 2.9 (26.6-29.2)
≥65 4.1 (44.4-49.) 4.1 (2.6-5.5) 2.1 (0.8-.4)
Sex
Male 44.1 (41.4-46.9) 51.1 (49.6-52.5) 2.0 (25.8-28.)
Female 55.9 (5.1-58.6) 49.0 (4.5-50.4) .0 (1.-4.2)
Race/ethnicity
Non-Hispanic white .0 (4.5-9.4) 8.1 (81.9-84.) .0 (5.-8.)
Non-Hispanic black 9.8 (8.4-11.4) . (.0-8.5) 9. (8.9-10.6)
Hispanic .5 (5.9-9.4) 5.5 (4.8-6.4) 9.1 (8.2-10.1)
Other 5. (4.4-.4) . (.1-4.) 4.1 (.5-4.8)
Education
Less than high school graduate 21. (19.-2.5) 15.9 (14.8-1.0) 16.6 (15.5-1.6)
High school graduate 6. (.8-8.9) 2.0 (0.-.4) 4.1 (2.9-5.4)
Some post–high school education 42.4 (9.-45.0) 52.1 (50.6-5.6) 49. (48.0-50.)
Self-assessed general health status
Excellent or very good 24.6 (22.4-2.0) 2.6 (1.2-.9) 5.1 (.8-6.4)
Good 0.8 (28.4-.) 2. (0.9-.) .4 (2.1-4.)
Fair or poor 44.6 (41.9-4.) 5.2 (.-6.6) 1.5 (0.2-2.8)
 
Abbreviation: CI, confidence interval. 
a Current smokers were respondents who reported smoking at least 100 cigarettes during their lifetimes and reported continuing to smoke at the time of the 
interview, former smokers were those who reported ever smoking at least 100 cigarettes but not smoking at the time of the interview, and never smokers 
were respondents who reported smoking fewer than 100 cigarettes in their lifetimes and did not smoke at the time of the interview. Values for n do not sum to 
6,522 because some respondents did not answer the question regarding smoking status.  
b Percentages were weighted to population characteristics. 
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Table 2. Association Between Smoking and Visual Impairment Among People With Age-Related Eye Diseases, Behavioral Risk 
Factor Surveillance System, 2005-2008
 Type of Smokera Prevalence,b % (95% CI) Unadjusted OR (95% CI) Adjusted ORc (95% CI)
Current 48.2 (45.6-50.9) 1.1 (1.16-1.48) 1.16 (1.02-1.2)
Former 41.2 (9.-42.6) 0.98 (0.91-1.0) 1.04 (0.95-1.1)
Never 41.6 (40.2-42.9) 1 [Reference] 1 [Reference]
 
Abbreviations: CI, confidence interval; OR, odds ratio. 
a Current smokers were respondents who reported smoking at least 100 cigarettes during their lifetimes and reported continuing to smoke at the time of the 
interview, former smokers were those who reported ever smoking at least 100 cigarettes but not smoking at the time of the interview, and never smokers were 
respondents who reported smoking fewer than 100 cigarettes in their lifetimes and did not smoke at the time of the interview. 
b Estimated crude rate of visual impairment among participants who were current, former, or never smokers. 
c Adjusted for age, sex, race/ethnicity, education levels, and general health status.
Table 3. Predictive Margin (Probability [%]) of Visual Impairment Among People With Age-Related Eye Diseases (Cataract, Glaucoma, 
AMD, or DR), by Smoking Status, Behavioral Risk Factor Surveillance System, 2005-2008
Type of Smokera
Cataract (n = 30,836), PM 
(95% CI)
Glaucoma (n = 5,622), PM 
(95% CI)
AMD (n = 4,943), PM (95% 
CI)
DR (n = 2,883), PM (95% 
CI)
Current 44.0 (41.2-46.9) 45.1 (8.0-52.2) 65.4 (59.2-1.5) 56.9 (49.4-64.4)
Former 41.2 (9.6-42.8) 4.9 (44.4-51.5) 60.1 (56.4-6.9) 58.0 (5.0-6.0)
Never 40.4 (9.0-41.9) 46.6 (4.0-50.1) 56. (52.9-60.4) 51.9 (4.0-56.8)
P Valueb .0 .2 .02 .2
 
Abbreviations: PM, predictive margin; CI, confidence interval; AMD, age-related macular degeneration; DR, diabetic retinopathy. 
a Current smokers were respondents who reported smoking at least 100 cigarettes during their lifetimes and reported continuing to smoke at the time of the 
interview, former smokers were those who reported ever smoking at least 100 cigarettes but not smoking at the time of the interview, and never smokers were 
respondents who reported smoking fewer than 100 cigarettes in their lifetimes and did not smoke at the time of the interview.  
b P values calculated by using t test, comparing current vs never smokers. 
